By Lucas Project Foundation
Read the original report’s PubMed record
A report about one person can open a research question. It cannot promise the same outcome for another family.
Published September 28, 2026, this case report describes an adolescent with cerebral ALD who received a transplant using expanded umbilical cord blood. “Expanded” means cells were increased in number outside the body before transplantation.
The donor cells took hold and began producing blood cells, a process called engraftment. At 18 months, the patient had a normal neurological examination. The course also included complications: bleeding and graft-versus-host disease, in which donor immune cells attack the recipient’s tissues. These details are part of understanding the reported outcome.
The manufacturer supplied the product through compassionate use for this patient, who had no alternative donor or treatment options. That access in one case does not establish routine availability for other families. Read the full case report.
Why the size of the report matters
This is one patient, not a trial comparing treatments. It does not establish that expanded cord blood is safer or more effective than other options, or tell another family whether it is appropriate or available for them.
The report also discloses manufacturer involvement: one author works for Gamida Cell, and another received company support to present the case.
If this raises questions about donor options, bring the paper to your ALD and transplant teams. They can explain its relevance to your situation, including risks and uncertainties.
Further reading: International ALD recommendations.